Clinical Trials in Follow-Up

  • AMEND

Description: A Phase 2, Double-Masked, Randomized, Placebo-Controlled, Dose-Response Study Assessing the Safety and Efficacy of AQ102 in Subjects with dry AMD

  • AMYDIS (OLIX)

Description: A Phase 1, Multicenter, Open-Label, Single- and Multi-Dose, Dose-Escalating Clinical Study to Evaluate the Safety and Tolerability of OLX10212 Administered by Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration

  • ASCLEPIX

Description: Phase 1/2a Study of the Safety and Bioactivity of AXT107 Injected Suprachoroidally in Subjects with Neovascular Age-Related Macular Degeneration (nAMD)

  • BP44241-RIVOL1

Description: A phase 1b, multicenter, randomized, double-masked, active comparator-controled study to investigate the biological activity, safety, tolerability, pharmacokinetics and pharmacodynamics of R07200394 in participants with macular edema secondary to central retinal vein occlusion

  • COAST

Description: A Phase 3, multicentre, double-masked, randomized study to evaluate the efficacy and safety of intravitreal OPT-302 in combination with aflibercept, between changes in retina function with the severity of diabetic retinopathy.

  • EDIC

Description: Epidemiology of Diabetes Interventions and Complications currently in year 30 of the trial

  • PAGODA

Description: A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Diabetic Macular Edema.

  • PORTAL

Description: A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration (Portal).

  • TEJAS/ ASHVATTHA THERA-PEUTICS

Description: A Two Stage Phase 2 Study: Stage 1: Single Subcutaneous Dose Open-label Assessment of Safety and Pharmacodynamic Response to D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor) in subjects with Neovascular (wet) Age-Related Macular Degeneration (AMD) or subjects with Diabetic Macular Edema (DME).